<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2014</study_start_year><condition>Colorectal Neoplasms</condition><condition>Patients That Have Been Diagnosed With Colorectal Cancer</condition><condition>Patients Eligible for Tumor Biopsy</condition><disease>Colorectal Neoplasms</disease><disease>Patients Eligible For Tumor Biopsy</disease><disease>Patients That Have Been Diagnosed With Colorectal Cancer</disease><study_type>Observational</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2140050</full_dataset_link><location>Israel</location><study_start_month>1</study_start_month><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>NovellusDx Tissue Collection Protocol</name><description>NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.</description><dates><creation>2014-01-15</creation></dates><accession>2140050</accession><cross_references><ClinicalTrials___gov>NCT01791322</ClinicalTrials___gov></cross_references></HashMap>